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Background: Hypocalcaemia, defined by serum calcium level less than 8.5 mg/dl, could be caused by human
immunodeficiency virus (HIV) and diarrheal diseases. In Ethiopia, while morbidities from diarrheal diseases and HIV
are serious health problems, studies assessing the interactions amongst of the three do not exist. Therefore, the
present study was undertaken to investigate the level of calcium among diarrheic patients with and without HIV
co-infection.
Methods: Consecutive diarrheic patients attending Gondar University Hospital in Ethiopia were enrolled and
screened for HIV, intestinal parasites, Shigella and Salmonella. Concentration of calcium in serum was determined
using an inductively coupled plasma mass spectrometer.
Results: A total of 206 diarrheic patients were included in the study (109 = HIV positive, 97 = HIV negative).
Intestinal parasites and Shigella species were detected in 32.2% and 8.5% of the patients, respectively. The serum
calcium levels in the patients who were found positive for Shigella species or intestinal parasites was not
significantly different by the presence or absence of HIV co-infection. HIV infected diarrheic patients had significantly
lower mean serum calcium levels (7.82 ± 1.23 mg/dl) than those negative for HIV (8.38 ± 1.97) (P = 0.015). The age
groups 25–35 and greater than 45 years showed significantly lower mean serum calcium levels (7.77 ± 1.55 mg/dl)
in comparison to the other age groups (7.84 ± 1.41 mg/dl, P = 0.009). On the other hand, females presented with
significantly lower mean serum calcium levels (7.79 ± 1.60 mg/dl, P = 0.044) than males (8.26 ± 1.65 mg/dl).
Conclusion: There is high prevalence of hypocalcaemia among diarrheic patients in northwest Ethiopia. And HIV
stood out to be a major risk factor for development of hypocalcaemia among the diarrheic patients in northwest
Ethiopia. Further studies are required to substantiate and characterize the mechanisms and consequences of
calcium metabolism disorders among HIV infected individuals in the study area.
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Diarrheal diseases, intestinal parasitic infections and en-
teropathogenic bacteria represent one of the six leading
causes of death worldwide [1] with an enormous dis-
eases burden associated with them [2,3]. They are also
one of among the important causes of morbidity and
mortality in developing countries [4]. The situation is se-
vere in sub-Saharan Africa, a region where an estimated* Correspondence: beyemoges@gmail.com
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unless otherwise stated.25.8 million adults and children are infected with human
immunodeficiency virus (HIV) [5]. HIV manifests with
chronic [4] and persistent diarrhea in which more than
half of the cases is due to intestinal parasites [6-9].
Disturbances of electrolyte metabolism and endocrine
regulation like hyponatraemia [10-12], hypo- and hyper-
kalaemia [13-18] have been observed in HIV patients.
In addition, lactic acidosis [19], hypophosphatemia, [20],
hypernatremia [21], and hypocalceamia [20,22] have also
been described. In a recent study conducted by our
group in northwest Ethiopia, hypercalcemia was wide-
spread among asymptomatic HIV infected patients [23].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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dilation, muscle function, nerve transmission, intracellu-
lar signaling and hormonal secretion. However, less than
1% of total body calcium is needed to support these crit-
ical metabolic functions [24]. Hypocalcaemia, defined by
serum calcium level less than 8.5 mg/dl [25], could be
caused by HIV infection [20,22,26]. Diarrheal diseases
could also cause hypocalcaemia through malabsorption
and sepsis [27-30]. In Ethiopia morbidities from diarrheal
diseases and HIV are serious health problems. However,
studies assessing the interactions between diarrheal dis-
eases, HIV and calcium metabolism do not exist. There-
fore, the present study was undertaken to investigate the
level of calcium among diarrheic patients with and with-
out HIV co-infection.
Methods
Consecutive diarrheic patients attending Gondar Univer-
sity Hospital in Ethiopia were enrolled. The University
teaching hospital is a major tertiary levels referral hospital
rendering health services for over 5 million inhabitants in
the Northwest Ethiopia. All HIV-infected patients were
naive to antiretroviral drugs at the time of data collection.
Patients with hyperparathyroidism and other known
calcium metabolism disorders were excluded from the
analysis.
Stool examination and culture
Stool specimens were collected following the standard
procedure [30]. Samples were then inoculated immedi-
ately on MacConkey and Salmonella-Shigella agar plates
(Oxoid). The inoculated plates were incubated at 37°C
aerobically for 24 hours. The plates were then examined
for the presence or absence of visible bacterial colonies.
The presence of non-lactose fermenting (NLF) colonies
was taken as a presumptive diagnostic tool for Shigella
and Salmonella species. The NLF colonies were further
tested through a series of biochemical tests followed to
identify Shigella and Salmonella species [31]. Proper micro-
biological quality control was employed at each step of the
procedure and American Type Culture Collection quality
control strains of Escherichia coli (ATCC 25922) and
Pseudomonas aeruginosa (ATCC 27853) were used. Stool
specimens were also processed and examined by direct mi-
croscopy for intestinal parasites. Modified acidfast staining
technique was also employed to detect Cryptosporidium
parvum and Isospora belli [32].
Blood collection, clinical chemistry and HIV serology
Blood specimens were taken with minimal venostasis after
overnight fasting for the measurement of serum calcium
from diarrheic patients. The presence of HIV antibodies
was determined by an enzyme linked immunosorbent
assay following the manufacturer’s instruction (VironosticaHIV Uni-Form II plus O, Organon Teknika, Boxtel, the
Netherlands). The concentration of albumin was determined
photometrically (AUTOLAB PM 4000/3, Analyser Medical
System, Italy). Hypoalbuminemia was defined as serum al-
bumin level below 3.5 gm/dl [33].
Determination of calcium in serum
The frozen serum samples were kept on dry ice and air
freighted to Japan. Concentration of calcium in serum
was determined using an inductively coupled plasma
mass spectrometer (ICP-MS) (model 8500, Schimadzu,
Tokyo, Japan), at Department of Analytical Chemistry,
the University of Tokushima, Japan [34]. In brief, serum
sample (200 μl) was aliquoted in to teflon tube and cov-
ered with teflon ball. After adding 1 ml of concentrated
HNO3 (Wako Pure Chemicals, Japan), the tube was
heated on an aluminum heating block (IWAKI, Asahi
Techno Glass, Japan) at 120°C for 5 h. The sample was
further heated almost to dryness at 200°C after remov-
ing the teflon ball. Finally, the residue was dissolved
with 2 ml of 0.1 M HNO3 which contained 10 ng/ml in-
ternal standard elements (In, Re and Tl). The diluted
serum solution was used for analysis of the calcium in
ICP-MS. Commercially available single element stand-
ard solutions (1000 mg/ml) were purchased from Wako
Pure Chemicals (Osaka, Japan) and used for standardization
of calibration curves. To allow for protein binding of cal-
cium, measured serum total calcium concentrations were
corrected for hypoalbuminemia using the following equa-
tion as published by [35]: Corrected Ca = serum Ca + 0.8
(4 - serum albumin).
Statistical analysis
Data were analyzed using SPSS version 16 statistical
package. A one-sample Kolmogorov– Smirnov test was
used to assess whether the data were normally distributed.
Serum calcium values were log transformed for analysis.
Comparisons of serum values of calcium among diarrheic
patients with and without HIV co-infection versus shigel-
losis/intestinal parasitoses groups were made using a one-
way ANOVA. Post-hoc Tukey test was used to determine
which pairs of means differ significantly. The independent
T-test was used to compare means among different
groups of diarrheic patients. Logistic regression and multi-
nomial regression models were used to check for statis-
tical association between dependent and independent
variables. Those variables which were found significantly
associated with the dependent variables were further
tested by controlling with other independent variables if
association is still maintained. Hypoclacemia was defined
as its serum levels less than 8.5 mg/dl while hypercalcemia
was defined at its serum levels greater than 10.5 mg/dl
[25]. P-values less than 0.05 were considered statistically
significant.
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The study was conducted after ethical approval was ob-
tained from Institutional Review Board of the University
of Gondar and the University of Tokushima, Tokushima,
Japan and after informed consent was obtained from
adult study participants or legal guardians of children.
Positive patients for shigellosis and intestinal parasitoses
were treated following the nation’s standard clinical man-
agement protocols.
Result
A total of 206 diarrheic patients were included in the
study; out of which 109 (52.9%) were with HIV infection,
47 (22.8%) were with isolated shigellosis/intestinal para-
sitoses, and 50 (24.3%) were without HIV, shigellosis,
and intestinal parasitoses infection. Among the 109 HIV
positive participants 76 (69.7%) were having only HIV
infection while 33 (30.3%) were having HIV-shigellosis/
intestinal parasitoses co-infection.
Table 1 shows the demographic and clinical character-
istics of the patients versus their mean serum calcium
levels. The mean ± SD serum calcium (mg/dl) of the par-
ticipants was 8.08 ± 1.60. Majority 128 (62.1%) of the
participants had hypocalcaemia while 14 (6.8%) patients
had developed hypercalcemia. The mean serum calcium
levels varied significantly among different age groups,
sex and HIV serostatus (P < 0.05) while other variablesTable 1 Demographic and clinical data and serum calcium lev
Parameters Serum calcium level
Normocalcemia
N = 64 (31.1%)
Hypocalcaemia




15-24 23(35.9) 22(17.2) 7
25-34 20(31.2) 61(47.7) 3
35-44 15(23.4) 28(21.9) 3
> = 45 6(9.4) 17(13.3) 1
Sex
Male 42(65.6) 73(57) 1
Female 22(34.4) 55(43) 2
Shigellosis
Yes 4(6.) 11(8.6) 3
No 60(93.8) 117(91.4) 1
Intestinal parasitoses
Yes 22(34.4) 40(31.2) 4
No 42(65.6) 88(68.8) 1
HIV serostatus
Yes 24(37.5) 81(63.3) 4
No 40(62.5) 47(36.7) 1
*P value is calculated from independent T-test and one way ANOVA.
N = number, HIV = human immunodeficiency virus, SD = standard deviation.didn’t show any difference (Table 1). The age groups
25–35 and greater or equal to 45 years showed signifi-
cantly lower mean serum calcium levels in comparison
to the other age groups with 7.77 ± 1.55 mg/dl and 7.84 ±
1.41 mg/dl, respectively (P = 0.009). Among those with
hypocalcaemia, 83.3% and 81.8% of those between 25–35
and > 45 years, respectively, had HIV infection. On the
other hand females presented with significantly lower
mean serum calcium levels (7.79 ± 1.60 mg/dl) than males
(8.26 ± 1.65 mg/dl) (P = 0.044). Among those with hypo-
calcaemia, 79.5% and 70.8% of women and men had HIV
infection, respectively. Having HIV was also associated
with significantly lower mean serum calcium levels in
comparison with not having HIV infection with 7.82 ±
1.23 mg/dl (P = 0.015) (Table 1).
Table 2 describes the albumin adjusted serum calcium
levels (mg/dl) among diarrheic patients with and without
HIV versus shigellosis and intestinal parasitoses. The
mean ± SD serum calcium level of those only with HIV
infection and with HIV-shigellosis/intestinal parasitoses
co-infection were 7.76 ± 1.29 mg/dl and 7.96 ± 1.09 mg/
dl, respectively. These low mean serum calcium levels
were significantly lower than those without HIV infec-
tion (P = 0.021) (Table 2).
Hypocalcaemia was found in 57 (75%) of those having
HIV, in 24 (72.7%) of those with HIV-shigellosis/intes-





Mean ± SD calcium P value*
0.009
(25.2) 52(25.2) 8.72 ± 1.83
(21.4) 84(40.8) 7.77 ± 1.55
(21.4) 46(22.3) 8.05 ± 1.52
(7.1) 24(11.7) 7.84 ± 1.41
0.0442(85.7) 127(61.7) 8.26 ± 1.65
(14.3) 79(38.3) 7.79 ± 1.60
0.857(21.4) 18(8.7) 8.15 ± 2.15
1(78.6) 188(91.3) 8.08 ± 1.59
0.672(28.6) 66(32) 8.01 ± 1.90
0(71.4) 140(68) 8.12 ± 1.51
0.015(28.6) 109(52.9) 7.82 ± 1.23
0(71.4) 97(47.1) 8.38 ± 1.97
Table 2 Serum levels of calcium (mg/dl) in diarrheic patients with HIV and without HIV versus shigellosis and intestinal
parasitoses in Gondar, Ethiopia
HIV (N = 76) HIV/shigellosis/IP (N = 33) Shigellosis/IP only (N = 47) Negative for allb (N = 50)
Mean ± SD* 7.76 ± 1.29 7.96 ± 1.09 8.06 ± 2.40 8.67 ± 1.42
Median (Range) 7.62(4.62-11.99) 8.03(6.26-10.68) 8.3(0.19-12.28) 8.58(3.16-12.08)
Cut-off value no (%) <8.5mg/dla 57(75) 24(72.7) 25(53.2) 22(44)
8.5-10.5mg/dl 16(21.1) 8(24.2) 16(34) 24(48)
>10.5mg/dl 3(4) 1(3.1) 6(12.8) 4(8)
aCutoffs according to [25].
bNegative for HIV, Shigellosis and intestinal parasitoses.
IP = Intestinal Parasitoses, HIV = human immunodeficiency virus, SD = standard deviation, N = number.
*P = 0.021 using one way ANOVA.
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the diarrheic patients without HIV and shigellosis/intestinal
parasitoses, 22(44%) developed hypocalcaemia (Table 2).
Regardless of co-infection with shigellosis or intestinal
parasitoses, hypocalcaemia was found among 81 (74.3%)
of those with HIV infection. Using the multinomial re-
gression model, HIV infection was found to be signifi-
cantly associated with hypocalcaemia (OR = 4.31, 95%
CI = 1.28-14.51). This statistical association persisted
even after controlling for other characteristics like sex,
age and shigellosis/intestinal parasitoses when separ-
ately added in the model (OR = 4.27, 95% CI = 1.25-
14.53; OR = 3.68, 95% CI = 1.05-12.86; and OR = 3.89,
95% CI = 1.12-13.51, respectively). Similarly, the associ-
ation persisted when only two other variables were
combined and added in the model (P < 0.05). However,
the association was lost when all parameters were added
together to the model (P > 0.05).
Among the 14 diarrheic patients with hypercalcemia, 3
(21.4%), 1 (7.1%), 6 (42.9%), and 4 (28.6%) were with
isolated HIV; HIV-shigellosis/intestinal parasitoses co-
infection; isolated shigellosis/intestinal parasitoses; and
without HIV, shigellosis or intestinal parasitoses, respect-
ively (Table 2). The development of hypercalcaemia didn’t
show any statistical association with any of the independ-
ent variables.
Discussion
Apart from the common hyponatremia, hypo- and hyper-
kalemia [10-21], hypocalcaemia is recently reported as one
of the multiple HIV associated electrolyte metabolism dis-
turbances [20,22]. Generally hypocalcaemia has not been
considered to be a frequent phenomenon in HIV infection
and used to be mostly attributed to hypoalbuminaemia or
to pharmacotherapy like foscarnet or ketoconazole [35-38].
In spite of this, the current study revealed high prevalence
of hypocalcaemia in HIV infected participants (74.3%)
than their negative counterparts (44%). The prevalence of
the hypocalcaemia in the current study is far much higher
than that reported from Germany (6.5%) [23]. One pos-
sible explanation for the high prevalence of hypocalcaemiaamong Ethiopia patients could be a dietary calcium defi-
ciency (ascribed to low consumption of dairy products
and a high-fibre diet). Another possible explanation might
be the dark skin pigmentation of the African people lead-
ing to decreased dermal synthesis of vitamin D. Hypocal-
caemia among HIV infected individuals could lead to
osteoporosis and other related bone disorders. This, how-
ever, demands further longitudinal investigations.
As reflected by reports from several studies, the causes
of hypocalcaemia in HIV infected patients could be
multifactorial and likely represent a complex interaction
between HIV infection, traditional hypocalcemic risk
factors exacerbated by consequences of chronic HIV in-
fection (eg, poor nutrition), low vitamin D levels and
drug related factors [37,39-46]. In the current study,
however, all the HIV infected participants were naïve to
antiretroviral therapy and didn’t receive foscarnet or
ketokonzole ruling out the effect of treatment associated
hypocalcaemia. We also excluded all patients with known
calcium metabolism disorders before the commencement
of the study. On the other hand, renal failure, pancreatitis,
malabsorption and sepsis have also been described as pos-
sible causes of hypocalcaemia during HIV infection [28-30].
Direct effects of HIV on the differentiation or activation
of osteoclasts could be one more possible explanation for
the hypocalcaemia. It is reported that HIV-1, Vpr, en-
hances production of receptor of activated NF-kappa B
ligand (RANKL) via potentiation of glucocorticoid recep-
tor activity [47] which activates formation of osteoclasts
and inhibits osteoclast apoptosis [48]. On the other hand,
persistent HIV infection or episodes of opportunistic in-
fections have been shown to result in chronic T-cell acti-
vation and a pro-inflammatory cytokine milieu [49,50]
that induces functionally active osteoclasts by expressing
both a cell-bound and a soluble form of RANKL [51,52].
Of note, RANKL gene expression is enhanced by cyto-
kines such as interleukin-1 (IL-1) and tumor necrosis fac-
tor alpha (TNF-α), which are elevated in HIV infection
[48,51]. Moreover, IL-1 and TNF-α are capable of directly
inducing differentiation and activation of osteoclasts in
the absence of RANKL [53,54]. In the current study, HIV
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1.28-14.51) with hypocalcaemia; direct effects of the virus
could be the primary mechanism for the hypocalcaemia.
However, further studies are required to substantiate the
causes and associated factors with hypocalcaemia in HIV
patients in the study area.
On the other hand, in the current study, 8.7% of the
participants had shigellosis that could result in to sepsis.
It has been suggested that hypocalcaemia could be the
result of an increased in IL-1 and TNF-α production, al-
though the underlying mechanisms are unclear [54,55].
Despite its potent ability to stimulate bone resorption,
IL-1 induces hypocalcaemia in mice and in rats [54,56],
leading to the hypocalcaemia seen during sepsis [54,56].
Lipopolysaccharide (LPS), a component of the cell-walls
of Gram negative bacteria like Shigella species, may
stimulate many biological activities in a wide variety of
cells via IL-1 and TNF [57]. Injection of sub-lethal doses
of LPS into wild type mice by Deng et al. [58] also in-
duced hypocalcaemia, increased IL-1, and increased
TNF-α. A time-lag between IL-1- and TNF-α-stimulated
Ca2+-entry into cells throughout the body from the cir-
culation and IL-1-stimulated Ca2+-release from the bone
was suggested to cause the observed LPS-induced hypocal-
caemia [59]. However, isolated shigellosis was not found to
be a risk factor for hypocalcaemia in the current study.
Bone is composed of matrix and osteoid, and it is miner-
alized with calcium and phosphate in the form of calcium
hydroxyapatite. When bone mineralization is decreased,
osteopenia can occur. Eventually, osteoporosis (i.e., porous
bone) can result. This is seen pathologically as the struc-
tural deterioration of bone and can lead to nontraumatic
fractures. Osteomalacia (i.e., soft bone) is most commonly
the result of vitamin D deficiency and occurs when intact
bone matrix is not adequately mineralized [60]. Among
the validated risk factors recognized for fragility fracture
in population studies is an increasing age [61,62]. In
the current study, however, apart from the elderly with
age greater than 45 years (mean serum calcium= 7.84 ±
1.41 mg/dl), the age groups 25–35 years showed signifi-
cantly lower mean serum calcium levels (7.77 ± 1.55 mg/dl)
in comparison to the other age groups (P = 0.009) (Table 1).
This low serum calcium levels in the elderly could be due
to aging itself which could further be exacerbated by HIV
infection as 81.8% of them have HIV infection. In the age
group 25–35 years, however, the low mean serum calcium
levels could mainly be due to HIV as 83.3% of them had
HIV infection. Low bone mineral density (BMD) has been
reported in many cross-sectional studies involving younger
[62] and older [63,64] HIV-infected individuals. Peak bone
mass is achieved during adolescence and young adulthood
and is a key determinant of bone mass in later life [65].
Thus, the effect of HIV infection and/or antiretroviral treat-
ment (ART) on this process is a critical area of research.In the HIV-negative people, BMD increases until around
age 30 where it remains stable for perhaps 5–10 years be-
fore starting to decline (at a rate of 0.5-1% per year), espe-
cially, in women during menopause (during which it
declines at −2% bone volume a year) [66]. Women gener-
ally have lower BMD than men [67]. In line with this, in
the current study, females presented with significantly
lower mean serum calcium levels than males with 7.79 ±
1.60 mg/dl (P = 0.044). Among those with hypocalcaemia,
79.5% and 70.8% of women and men had HIV infection,
respectively.
Our study also revealed that 6.8% of the diarrheic pa-
tients had hypercalcaemia. Four (28.6%) of them were
with HIV infection. This is in contrast to a report by our
group which showed 56.3% of hypercalcemia among
asymptomatic HIV infected individuals in northwest
Ethiopia [25]. However, the participants in the current
study were diarrheic patients which might play its part
to the reduced serum calcium level. The mechanism of
HIV associated hypercalcemia is not well established but
Acquired immunodeficiency syndrome (AIDS)-related
opportunistic infections (OIs) may lead to hypercalcemia.
Infection with Pneumocystis carinii [68], Mycobacterium
avium [69], lymphoma [70], Cryptococcus neoformans and
Coccidioides immitis [71,72], Candidiasis and paracocci-
dioidomycosis [73] and concurrent Epstein-Barr virus in-
fection [74] have all been reported to be associated with
hypercalcemia in HIV patients though we didn’t detect
any of them in the current study. It is interesting to note
that ART–induced immune reconstitution may lead to
the possibility of hypercalcemia [75,76]. The roles of cyto-
kines, OIs, ART-associated immune reconstitution inflam-
matory syndrome in the pathogenesis of hypercalcemia
among HIV/AIDS patients require further investigation.
In summary, there was a high prevalence of hypocalcae-
mia among diarrheic patients in northwest Ethiopia. HIV
was a significant factor for development of hypocalcaemia
in the study area. HIV associated malabsorption, sepsis,
and direct effect of the virus on calcium metabolism could
be the mechanisms of hypocalcaemia. However, further
studies are required to substantiate how HIV is associated
with a high prevalence of hypocalcaemia in the study area.
Limitation of the study
The fact that the study was a cross sectional study it re-
stricted the generalization we made. We didn’t also
measure the serum Vitamin D level as its deficiency is a
well established risk factor for hypocalcaemia though
there is a reportedly high rate of biochemical vitamin D
deficiency among Ethiopians [77] which could partly be
associated with the dark skin pigmentation leading to
decreased dermal synthesis of vitamin D [78]. We didn’t
also measure the BMD of the participants to substantiate
the long term effect of hypocalcaemia among HIV patients
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ther studies by addressing all the aforementioned gaps.
Conclusion
There is high prevalence of hypocalcaemia among diar-
rheic patients in northwest Ethiopia. HIV stood out to
be a major risk factor for development of hypocalcaemia
among the diarrheic patients. Direct effects of the virus
on calcium metabolism, sepsis, and malabsorption could
be the mechanisms of hypocalcaemia. The high preva-
lence of the hypocalcaemia among HIV infected individ-
uals could result in to bone disorders. However, further
studies are required to substantiate and characterize the
mechanisms and consequences of calcium metabolism
disorders among HIV infected individuals.
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